Trial Profile
A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna; Pegfilgrastim
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 20 Feb 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.